8 July 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION (EACH A “RESTRICTED JURISDICTION”).
This announcement is not and does not constitute or form part of, and should not be construed as, an offer of securities for subscription or sale in any jurisdiction nor a solicitation of any offer to buy or subscribe for, any securities in any jurisdiction, including in or into any Restricted Jurisdiction, nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This announcement is not an admission document or prospectus and does not constitute a recommendation regarding any securities. Terms capitalised in this announcement but not defined herein shall have the meaning given to them in the admission document published by the Company on 2 July 2021 (the "Admission Document").
LungLife AI, Inc.
(the “Company” or “LungLife”)
Admission to trading on AIM
& First Day of Dealings
LONDON, UK. AND THOUSAND OAKS, CALIFORNIA, US (8 July 2021). LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that admission to trading on AIM (“Admission”) will take place and dealings will commence at 8.00 a.m. today under the ticker LLAI and ISIN USU5500L1045.
Summary and Highlights: